Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors
Malignant brain tumors are fast growing and are known to spread to other areas of the brain and spine. These brain tumors are often graded based on how fast they grow and their likelihood of growing back following treatment. The most common type of malignant brain tumor are gliomas, which make up more than 75% of brain tumors.
During the 27th annual meeting of the Society for Neuro-Oncology, data on the rise observed in the mortality rate of patients with primary malignant brain tumors was presented.
For their research, the investigators conducted an analysis of mortality data obtained from the Surveillance, Epidemiology and End Results (SEER) program by the National Cancer Institute and the National Cancer for Health Statistics’ National Vital Statistics System (NVSS). The researchers found that in the period between 2004 and 2018, the overall annual percentage change in mortality among brain tumor patients was 0.4% and 0.3% in the SEER and NVSS cohort respectively.
The report also observed that the rise in mortality was primarily driven by patients aged 15 to 39, noting that the annual percent change in this group was 0.9% and 0.4% in the SEER and NVSS cohort respectively. These figures are high, especially when compared to the mortality rate among patients aged 40 to 64, which stood at 0.2% and 0% for the respective cohorts. Mortality in patients up to age 14 stood at 0% in the SEER cohort and -0.01% in the NVSS cohort.
The researchers also observed differences in mortality by sex, noting that the percentage change in the period between 2004–2016 and between 2016–2018 for women in the SEER cohort stood at 0.6% and -3% respectively. On the other hand, the annual percentage change during 2004–2018 for women in the NVSS cohort stood at 0.3%. In men, the percentage change in the same period was 0.3% for both cohorts.
The annual percentage change was also different in White and Black individuals. Researchers observed that it was 0.5% and 0.4% in White individuals in the SEER and NVSS cohorts respectively, and 0.3% and 0.7% in Black individuals in the SEER and NVSS cohorts.
The data also showed that mortality rates were highest in American Indian/Alaskan Native and Asian/Pacific Islander patients, with researchers noting that the annual percentage change in this group stood at 1% and 1.6% in the SEER and NVSS cohorts respectively.
The study was partly funded by Novocure, an oncology company pioneering new therapies for solid tumors.
These rising fatalities due to brain cancers gives context to the massive investments being made by enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) with the aim of commercializing better treatments for these cancers.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Malignant brain tumors are fast growing and are known to spread to other areas of the brain and spine. These brain tumors are often graded based on how fast they grow and their likelihood of growing back following treatment. The most common type of malignant brain tumor are gliomas, which make up more than 75% of brain tumors.
During the 27th annual meeting of the Society for Neuro-Oncology, data on the rise observed in the mortality rate of patients with primary malignant brain tumors was presented.
For their research, the investigators conducted an analysis of mortality data obtained from the Surveillance, Epidemiology and End Results (SEER) program by the National Cancer Institute and the National Cancer for Health Statistics’ National Vital Statistics System (NVSS). The researchers found that in the period between 2004 and 2018, the overall annual percentage change in mortality among brain tumor patients was 0.4% and 0.3% in the SEER and NVSS cohort respectively.
The report also observed that the rise in mortality was primarily driven by patients aged 15 to 39, noting that the annual percent change in this group was 0.9% and 0.4% in the SEER and NVSS cohort respectively. These figures are high, especially when compared to the mortality rate among patients aged 40 to 64, which stood at 0.2% and 0% for the respective cohorts. Mortality in patients up to age 14 stood at 0% in the SEER cohort and -0.01% in the NVSS cohort.
The researchers also observed differences in mortality by sex, noting that the percentage change in the period between 2004–2016 and between 2016–2018 for women in the SEER cohort stood at 0.6% and -3% respectively. On the other hand, the annual percentage change during 2004–2018 for women in the NVSS cohort stood at 0.3%. In men, the percentage change in the same period was 0.3% for both cohorts.
The annual percentage change was also different in White and Black individuals. Researchers observed that it was 0.5% and 0.4% in White individuals in the SEER and NVSS cohorts respectively, and 0.3% and 0.7% in Black individuals in the SEER and NVSS cohorts.
The data also showed that mortality rates were highest in American Indian/Alaskan Native and Asian/Pacific Islander patients, with researchers noting that the annual percentage change in this group stood at 1% and 1.6% in the SEER and NVSS cohorts respectively.
The study was partly funded by Novocure, an oncology company pioneering new therapies for solid tumors.
These rising fatalities due to brain cancers gives context to the massive investments being made by enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) with the aim of commercializing better treatments for these cancers.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
